Casirivimab/Imdevimab - An Indian Real World Experience : Review Dr. Kamal Kant Kohli10 Jun 2022 6:19 AM GMTThe antibody cocktail (Casirivimab and Imdevimab) has been approved in India for the treatment of mild to moderate COVID-19 in adolescents and adults...
Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2 Dr. Kamal Kant Kohli16 May 2022 6:15 AM GMTThe omicron (B.1.1.529) variant of SARS-CoV-2, has spread rapidly around the world and has already become the predominant variant circulating in many...
Decoding REGEN-COV2 for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients Dr. Kamal Kant Kohli17 March 2022 6:15 AM GMTKidney transplant recipients are an immunocompromised population, with comorbid conditions such as obesity, diabetes, and coronary artery disease,...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19: RECOVERY Trial Dr. Kamal Kant Kohli9 March 2022 11:49 AM GMTCasirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor-binding domain of the SARS-CoV-2...
Review: Antihypertensive Amlodipine for tackling circadian fluctuations of BP dr. Abhimanyu Uppal8 Feb 2022 5:52 AM GMTHypertension is the most powerful risk factor for cardiovascular diseases, including stroke, coronary artery disease, heart failure, chronic kidney...
Decoding safety, tolerability, and pharmacokinetics of Molnupiravir Dr. Kamal Kant Kohli4 Feb 2022 6:26 AM GMTMolnupiravir is a prodrug of active antiviral ribonucleoside analog b-D-N4-hydroxycytidine (NHC; EIDD-1931), with the potential to treat infections...
Quick Review: Effectiveness of REGEN-COV antibody cocktail against B.1.617.2 (delta) variant of SARS-CoV-2 Dr. Kamal Kant Kohli1 Feb 2022 7:04 AM GMTCasirivimab plus imdevimab antibody cocktail (REGEN-COV) has been shown to reduce viral load and prevent symptomatic disease in household contacts of...
Molnupiravir (MK-4482/EIDD-2801) inhibits SARS-CoV-2 replication in Syrian Hamster Model Dr. Kamal Kant Kohli25 Jan 2022 5:34 AM GMTAn effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in...
Understanding Monoclonal Antibody in Treatment of Hospitalized Patients with COVID-19 Dr. Kamal Kant Kohli18 Jan 2022 7:15 AM GMTHospitalized COVID-19 patients reported having high mortality rates (10-30%). Casirivimab and imdevimab antibody cocktail (REGEN-COV®) are authorized...
Disease Review: Understanding Incidence of Idiopathic pulmonary fibrosis (IPF) in India, Diagnosis and Treatment Dr. Anil Mehndiratta10 Jan 2022 6:54 AM GMTIdiopathic pulmonary fibrosis (IPF), previously known as "Hamman Rich syndrome", "cryptogenic fibrosing alveolitis", and "cirrhosis of the lung", is a...
Amoxicillin In Review - Standing the Test of Time since Five Decades Dr. Kamal Kant Kohli22 Dec 2021 5:33 AM GMTAmoxicillin - Prime Choice of Agent in Primary Care SettingsAmoxicillin is regarded as one of the most widely and frequently used antibiotics,...
What was the optimal dose of pirfenidone in large studies on idiopathic pulmonary fibrosis? Dr. Kamal Kant Kohli9 Dec 2021 6:30 AM GMTIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease that is characterized by the irreversible loss of lung function....
